Gopinath M. Ranganna
Bengaluru, KA, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability.
Journal: Advances in therapy
Published: March 10, 2025
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.
Journal: European journal of drug metabolism and pharmacokinetics
Published: September 10, 2023
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: August 23, 2022
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
Journal: Diabetes, obesity & metabolism
Published: April 27, 2021
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: April 14, 2021
Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: March 08, 2021
The Path Towards a Tailored Clinical Biosimilar Development.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 09, 2020
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Journal: Annals of hematology
Published: October 26, 2018
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Journal: Journal of cancer research and clinical oncology
Published: March 19, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026